KR KRSNAA
Krsnaa Diagnostics Q4 2025
KRKRSNAA

Krsnaa Diagnostics Q4 FY25 results (Jan–Mar 2025) and concall

Healthcare · Concall AI · Call held 13 May 2025

Management summary

  • Krsnaa Diagnostics reported a robust FY25, with revenue growing 16% to ₹7,172 million and EBITDA expanding 370 bps to 27%.
  • Net profit saw a significant 37% increase.
  • Despite missing its revenue growth aspiration due to project delays and strategic tender decisions, the company demonstrated strong operational efficiency and rapid retail expansion.
  • Management expressed confidence in improving receivables and continued margin expansion in the upcoming quarters.

Source: Inve concall analysis and management guidance record.

Highlights

  • FY25 Revenue grew 16% YoY to ₹7,172 million, driven by increased awareness, patient volumes, and pricing efficiency.

  • FY25 EBITDA increased 34% YoY to ₹1,958 million, with margins expanding by 370 basis points to 27%, reflecting strong operating leverage.

  • FY25 Net Profit grew 37% YoY to ₹776 million, achieving an 11% margin.

  • Q4 FY25 Revenue grew 12% YoY to ₹1,861 million, and EBITDA grew 23% YoY to ₹542 million with a 29% margin.

What they filed

₹ Cr · quarterly
Line itemQ3 FY25Q4 FY25
Revenue9 10
EBITDA48 53
Net profit22 21
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Revenue

  • Revenue Growth Revenue · FY26 · Medium confidence better than the industry

Margin

  • EBITDA Margin Margin · upcoming quarters · Medium confidence continue to improve

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

1 direct
Radiology Business Growth and FY27 Projections Direct
The market is not slowing down. What we've done is we've been very careful and calibrated in terms of showing what are the realistic numbers. The market, as I mentioned earlier, in fact, from a government policy perspective, the government wishes to have more than 2,000 radiology

Analyst questioned the slower growth in radiology and conservative FY27 projections, prompting management to clarify their strategic, calibrated approach to growth and market potential.

Asked by Lokesh Manik

Retail Venture Revenue Potential and Network Definition Partial
However, giving out the outlook for '27 revenue numbers, it's a little too early for now, because the entire business and the structures and the systems are getting into the place. But with the initial one year centers or the touch points that we have formed up, we have laid down

Analyst sought specific revenue targets for the retail segment and clarification on the network model, to which management provided qualitative optimism and explained the evolving nature of their 'touch points'.

Asked by Lokesh Manik

Unlock risks & concerns, Q1 FY26 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 9 risks, concerns & management red flags
  • 5 watchlist triggers for Q1 FY26
  • +5 more guidance targets & verbatim management quotes
  • +6 more analyst Q&A exchanges & evasion checks
  • Capital allocation & full section-by-section narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image